SAGE PRO

Home / Research / Aster DM Quality Care Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Aster DM Quality Care Limited — Q2 FY27 Results Analysis

Quarterly combined revenue and operating EBITDA are higher

Published · Quarter Q2 FY27 · ASTERDM

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Combined revenue

Q2 FY26₹2,382 crore
Q2 FY27₹2,829 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 2

Operating EBITDA

Q2 FY26₹545 crore
Q2 FY27₹678 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 3

Operating EBITDA margin

Q2 FY2622.9%
Q2 FY2724%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 4

Normalized PAT after NCI

Q2 FY26₹210 crore
Q2 FY27₹281 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Quarterly combined revenue and operating EBITDA are higher

Revenue and operating profit grew on comparable issuer pro-forma basis

Watch: Verify the statutory-to-operating bridge

RESEARCH INSIGHT

Issuer-defined operating EBITDA rose 25%

Growth reflects utilization and mix, with excluded expenses

Watch: Check adjustment consistency

RESEARCH INSIGHT

Margin rose 111 basis points

Do not compare with unadjusted statutory EBITDA

Watch: Monitor recurring margin

RESEARCH INSIGHT

Post-NCI normalized profit grew 34%

Exceptional merger costs are excluded

Watch: Demand a statutory bridge

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Aster DM Quality Care | Q2 FY27 | Quarter ended 30 September 2026 | Stance: WATCH. The first complete operating quarter after the merger is an unusually informative but accounting-complex baseline. Management's combined, like-for-like presentation reports revenue of ₹2,829 crore (+19% year on year), operating EBITDA of ₹678 crore (+25%), operating margin of 24.0% (+111 basis points), and normalized profit after non-controlling interests of ₹281 crore (+34%). These are NOT statutory year-on-year growth comparisons: the merger became effective 1 July 2026, and prior statutory comparatives were not restated. The issuer constructed pro-forma combined prior-period figures to show economic momentum. [S1]

Decision in 30 seconds. WATCH the network's ability to turn occupancy, clinical complexity and procurement synergies into recurring cash after expansion spending. Do not equate the reported 24% operating margin with statutory EBITDA or the normalized ₹281 crore with statutory profit. No stock price, market capitalization, enterprise value or valuation multiple is supplied by the accepted sources; a defensible entry price cannot be calculated here. A valuation premium would require repeatable cash conversion, sustained patient growth and capital-efficient bed commissioning, rather than a single integration quarter.

Key quantified takeaways:

  • Q2 patient volume reached 2.18 million versus 1.95 million, a 12% increase on the combined basis. [S1]
  • Operational beds were 10,611 versus 10,222, approximately 4% growth; occupancy improved from 65% to 68%. [S1]
  • H1 combined revenue was ₹5,429 crore, operating EBITDA ₹1,255 crore and normalized post-NCI PAT ₹457 crore. [S1]
  • Synergies realized in Q2 were ₹16.6 crore, equivalent to management's approximately ₹65 crore annualized run rate, against an aspirational ₹200 crore full potential. [S1]
  • Gross debt was ₹3,959 crore and cash, bank balances and current investments ₹2,240 crore on 30 September 2026, leaving net debt ₹1,719 crore. [S1]
  • The announced 4,230-bed pipeline would lift stated capacity from 10,840 toward 15,000; this is a development plan, not operating capacity today. [S1]

What could change the view: a sustained rise in occupancy and revenue per operating bed without an offsetting jump in clinical staffing and equipment costs; measurable net-debt discipline while commissioning the pipeline; and evidence that merger savings remain after the initial low-hanging procurement efficiencies. The following seven chapters distinguish reported issuer figures, management targets and our conditional interpretation.

Chapter 1 — Investor decision and valuation discipline

The investment case rests on three interacting engines: more patients treated in existing hospitals, greater complexity of treatment per patient, and scale benefits from combining Aster, CARE, KIMSHEALTH and Evercare. Each engine can reinforce the others, but each can also disappoint independently. Q2 showed strong patient demand with relatively modest operational bed additions, suggesting that the near-term improvement was not solely a capacity effect. Yet occupancy of 68% still leaves room for utilization gains before the next large commissioning cycle. [S1]

Investment decision: maintain WATCH rather than imply a buy at an unknown market price. The appropriate valuation question is whether incremental operating profit can finance the coming 4,230-bed program without deteriorating leverage or diluting return on capital. The issuer's 23.0% quarter ROCE uses a defined capital-employed denominator excluding several categories including work in progress, goodwill and intangibles; it is not directly interchangeable with an all-in economic return on invested capital. [S1]

Tests before paying a premium:

  • Demand durability: patient growth must remain above operational bed growth as the network matures.
  • Margin quality: operating EBITDA gains must survive the normalization of merger-related exclusions and incremental costs of new units.
  • Capital discipline: report net debt including and excluding leases, and cash generation after maintenance and growth capital expenditure.
  • Synergy conversion: management's ₹200 crore potential must translate into documented quarterly realization, not just annualized claims.

The principal reason to hesitate is not a lack of growth; it is the interaction of pro-forma comparisons, new-hospital ramp costs, and large planned capital commitments. A quarterly improvement in operating EBITDA is encouraging but does not alone establish equity value creation.

Chapter 2 — Financial performance and earnings quality

The issuer presentation supplies an explicitly combined pro-forma comparative for Q2 FY26. Against that basis, revenue increased from ₹2,382 crore to ₹2,829 crore; operating EBITDA from ₹545 crore to ₹678 crore; and normalized post-NCI PAT from ₹210 crore to ₹281 crore. Operating EBITDA margin advanced from 22.9% to 24.0%.

The operating EBITDA series excludes other income and, for Q2 FY27, certain ESOP costs, variable O&M fees and other expenses. Normalized PAT excludes merger-related exceptional expenses and the share of loss from equity-accounted investees. These exclusions are economically material when assessing the sustainability of the stated profit margin. [S1]

MeasureQ2 FY26 combined pro formaQ2 FY27 combinedInterpretation
Revenue (₹ crore)2,3822,829+19% on issuer's combined basis
Operating EBITDA (₹ crore)545678+25%; issuer-defined operating metric
Operating EBITDA margin22.9%24.0%+111 basis points, issuer rounding
Normalized PAT after NCI (₹ crore)210281+34%; not statutory PAT
Patient volume (million)1.952.18+12%
Operational beds10,22210,611+4%
Occupancy65%68%+335 basis points before rounded display

Half-year performance: management reports H1 FY27 combined revenue of ₹5,429 crore (+20%), operating EBITDA ₹1,255 crore (+27%), operating margin 23.1% (versus 21.8%) and normalized post-NCI PAT ₹457 crore (+27%). These are issuer-defined combined comparisons, not restated statutory historical statements. [S1]

Earnings-quality questions:

  • How much of the ₹133 crore increase in quarterly operating EBITDA comes from recurring pricing, procedure mix and occupancy versus integration actions?
  • Are ESOP and O&M exclusions stable, or will the bridge from operating EBITDA to reported EBITDA widen?
  • Does normalized PAT after NCI translate into attributable operating cash after working-capital changes and equipment investment?
  • At the full-year release, do revised comparative audited figures alter the stated combined growth rates?

The most important accounting caveat is specific: Quality Care entered the reported consolidated results on 1 July 2026 under pooling of interests, but prior reported periods were not restated. Readers should not calculate statutory YoY growth from the presented combined pro-forma numbers.

Chapter 3 — Hospital economics, specialties and channel mix

The operating story is about increasing throughput and higher-acuity procedures across a network of brands rather than merely adding buildings. Total Q2 patient volume reached approximately 2.18 million, while the operational bed base grew just 4%. The issuer reports a 335-basis-point occupancy improvement to 68%, supporting fixed-cost absorption across hospitals. Average length of stay was 3.3 days in both comparative quarters, so the occupancy improvement is not simply a longer-stay artifact. [S1]

Maturity matters. Mature hospitals represented approximately 64% of operational beds but produced 73% of hospital revenue and 83% of operating EBITDA in the H1 mix described by management. Their revenue grew 18% and patient volume 11%. Focus hospitals represented 15% of beds and revenue, with 13% revenue growth and 7% volume growth. Emerging hospitals represented around 10% of beds and 6% of revenue, but reported 62% revenue growth and 53% volume growth from a smaller base. Underperforming hospitals grew revenue 24% and more than doubled operating EBITDA according to management; no precise starting EBITDA is provided. [S1]

Complex care: robotic surgeries grew 39%, kidney transplants 31% and joint replacements 29% in the period management described. These are activity growth rates, not segment revenue or margins; the accepted presentation does not permit assigning specific incremental profits to each procedure type. Medical value travel revenue grew 36% year on year, with Maldives and Gulf markets prominent and West Africa and other MENA markets contributing. [S1]

Economic implications:

  • Mature units are the near-term cash-generation backbone and should be evaluated on occupancy, mix and maintenance capital needs.
  • Emerging units offer faster percentage growth but need time to absorb fixed clinical teams and depreciation.
  • The mix shift to complex care can support revenue per admission, yet requires investment in clinicians, robots, imaging and oncology equipment.
  • International patient growth may improve revenue mix but introduces dependence on travel flows, referral relationships and payer conversion.

The company operates across 27 cities and reports 10,840 capacity beds, distinct from 10,611 operational beds. The difference is important: a capacity bed is not automatically staffed, commissioned or earning revenue.

Chapter 4 — Execution, milestones and management Q&A

The merger's first 100 days were framed around preserving clinical continuity while integrating purchasing, clinical talent and operating practices. Management reported 2.2 million patients served, no disruption to patient care, and a broad effort to standardize performance across four hospital brands. These are management statements; the next proof point is measurable unit economics rather than cultural integration slogans. [S1]

The Q2 synergy achievement was ₹16.6 crore, which management annualized to about ₹65 crore. In analyst Q&A, executives described a potential ₹200 crore full synergy opportunity, with an ambition to reach that level on an annualized run-rate basis over roughly the next three to four quarters; actual full realization could take longer. That timing is management guidance, not reported earnings. Procurement, medical material costs, clinical sharing, indirect spending, F&B insourcing, IT and energy efficiency were identified as levers. The company did not provide a reliable rupee allocation by lever. [S1]

Milestones to monitor:

  • The 454-bed Aster Trivandrum project was included in the FY27 expansion program and described as on schedule, but future commissioning should be confirmed in filings.
  • The 32-bed CARE Cancer Institute in Raipur was commissioned, alongside specialty centers including robotic spine and fetal medicine capabilities.
  • During Q2, the network added one LINAC, one digital PET-CT, three surgical robots, two cath labs and one MRI, evidence of the investment required for a higher-complexity case mix.
  • Management described more than ₹600 crore spent on medical technology over 18 months, a historical aggregate rather than Q2 expense.

Analyst challenge: a question on whether centralized procurement would produce 10% or 20% savings did not receive a precise disclosed savings percentage. Management instead emphasized the wider synergy wheel. Therefore, do not model an unsupported fixed procurement-margin improvement. Another question probed the timing of ₹200 crore synergy potential; the response distinguished run-rate attainment from full realized benefits. Investors should make that distinction in each future quarter.

Chapter 5 — Cash, leverage, capital expenditure and payback

At 30 September 2026, management reported gross debt of ₹3,959 crore and cash, bank balances and current investments of ₹2,240 crore, implying net debt of ₹1,719 crore. Management's trailing-twelve-month net debt/EBITDA was 0.87 times excluding lease liabilities and 1.72 times including leases. Those ratios use different liability bases and should not be conflated. [S1]

The combined network invested approximately ₹400 crore in H1 FY27 capex, mainly on ongoing projects with the balance on medical equipment. Management also referenced more than ₹1,200 crore of project, growth and refresh capex over the preceding 18 months. Neither figure is a free-cash-flow measure. The source excerpts do not provide a fully reconciled operating cash flow, maintenance capex, working capital bridge or project-level payback schedule; a precise cash-conversion ratio and IRR would be invented. [S1]

Expansion financing discipline: the stated 4,230-bed pipeline comprises roughly 47% brownfield and 53% greenfield capacity. Brownfield additions may leverage existing referrals, infrastructure and brand recognition; greenfield facilities typically require a longer occupancy ramp. These are economic hypotheses, not management-certified returns. The network's current 10,840 capacity beds and 10,611 operational beds must not be added to the pipeline indiscriminately when measuring future occupancy. [S1]

Capital tests:

  • Compare net debt and gross debt each quarter with the stated capex program, not operating EBITDA alone.
  • Track cash and liquid investments separately from financing availability and committed project spending.
  • Request operational opening dates and occupancy ramps for each major brownfield and greenfield project.
  • Evaluate return on incremental invested capital after commissioning, including relevant capital work in progress and leases.

The central risk is a temporary mismatch between capex cash outflows and the contribution from new beds. A margin-led investment thesis can still fail if cash investment rises faster than durable hospital cash generation.

Chapter 6 — Conditional outcomes and falsification

Bull case, conditional: patient growth remains well above operational bed additions, the higher-acuity case mix persists, mature units sustain margin expansion, and realized synergy savings progress toward management's ₹200 crore potential without being offset by rising clinical staffing and integration costs. Occupancy stays firm while new capacity is absorbed. This would strengthen the argument for a quality premium, but the sources do not establish a price target or multiple. [S1]

Base case, conditional: the company maintains healthy demand and continues to open new units, but integration benefits emerge unevenly and the incremental margin from mature hospitals is partly consumed by early-stage greenfield costs. Operating EBITDA still grows, but cash conversion and net debt remain the decisive valuation checks. The reported Q2 24.0% operating margin should not be extrapolated mechanically through an expansion cycle. [S1]

Bear case, conditional: medical equipment and project spending remain elevated, new units take longer to fill, procurement savings plateau, or staff and doctor retention costs rise. In this scenario, reported patient growth may coexist with weaker returns on capital and higher lease-adjusted leverage. The bearish thesis is falsified if future filings demonstrate both improved cash conversion and a profitable ramp at new facilities.

Quantified anchor points, not forecasts: 68% occupancy; 10,611 operational beds; ₹1,719 crore net debt; ₹400 crore H1 capex; ₹16.6 crore realized quarterly synergies; and 4,230 planned beds. No assumed annual revenue growth, terminal multiple, equity price or earnings forecast has been inserted. Each scenario describes the conditions investors should test rather than assigning unsupported probabilities.

Falsifiers to track:

  • For the bull case: two consecutive quarters of falling occupancy or materially weaker operating leverage despite stable volume growth.
  • For the base case: evidence of significantly faster net-debt reduction and strong incremental cash returns would warrant reassessment upward.
  • For the bear case: stable lease-inclusive leverage, delivered project milestones and documented synergy realization would weaken the downside thesis.

The largest uncertainty is the economic cost of integration and expansion, not the arithmetic of the headline growth figures.

Chapter 7 — Investment action plan and monitoring dashboard

Current action: WATCH, with a quarterly evidence checklist rather than a speculative entry price. The next release should be read against the same combined/pro-forma basis, with a separate bridge to statutory consolidated earnings. Ask management to reconcile operating EBITDA adjustments and normalized post-NCI profit with reported accounting results before using either as a valuation numerator. [S1]

MonitorQ2 FY27 issuer baselineDecision use
Combined revenue₹2,829 croreSeparate volume from pricing and mix
Operating EBITDA margin24.0%Check adjustment consistency and mature-unit economics
Patient volume2.18 millionTest demand versus operational bed additions
Occupancy68%Test utilization and operating leverage
Capacity / operational beds10,840 / 10,611Track conversion to earning beds
Net debt₹1,719 croreCompare with actual capex and cash generation
Lease-inclusive net debt/EBITDA1.72xWatch full financing burden
Realized quarterly synergies₹16.6 croreVerify sustainable integration benefits
Pipeline4,230 bedsMonitor commissioning and payback

Next-quarter action tests:

  • Confirm whether occupancy remains near or above the Q2 68% level as beds are commissioned.
  • Track quarterly patient volumes, advanced-procedure activity and medical value travel separately; do not assume equal margins.
  • Require the absolute rupee amount of realized synergies, rather than relying only on an annualized run rate.
  • Compare project openings, planned beds and operational beds to identify slippage or unusually slow ramp-up.
  • Track lease-inclusive leverage and operating cash after growth capex; escalate caution if debt rises without corresponding commissioned capacity.
  • Watch any restatement or revised comparative basis at the full-year result and update the historical growth interpretation accordingly.

Investment conclusion: the merger has produced credible initial scale and operating-leverage signals, but the value-creation test is still ahead. Q2 demonstrates demand and a promising integration start; the investment decision requires verified cash conversion and sustained post-expansion returns. No current market price or independent valuation is included in the accepted source set, so this is a monitoring plan, not a buy/sell or price-target call.

Original issuer filing and evidence limitations

[S1] BSE investor presentation for Q2 and H1 FY27, filed 6 November 2026. This filing contains the issuer's financial, operating, capacity and synergy exhibits. The associated 6 November management earnings discussion was used for Q&A interpretation; its internally accepted text is not reproduced or linked to a third-party transcript host. The original issuer/exchange transcript URL was not available in the accepted source ledger. The document provenance and text fingerprints remain private. The issuer explicitly uses combined pro-forma historical comparatives and adjusted operating-profit definitions. Full project-level cash payback, statutory cash-flow reconciliation and live valuation inputs are not provided in the extracted evidence used for this report.

[S2] Management earnings-call transcript, 6 November 2026 (internally archived full text). The original issuer-hosted transcript URL was not available; this source is identified for provenance but is not linked to a third-party mirror.

Additional company evidence

CHART 5

Total patient volume

Q2 FY261.95 million
Q2 FY272.18 million

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 6

Operational beds

Q2 FY2610,222 beds
Q2 FY2710,611 beds

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 7

Occupancy

Q2 FY2665%
Q2 FY2768%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

CHART 8

H1 FY27 financial measures

Revenue₹5,429 crore
Operating EBITDA₹1,255 crore
Normalized PAT₹457 crore

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.